全球诱导多能干细胞市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按衍生细胞类型、按应用、最终用户按地区和竞争细分

2022 年，全球诱导多能干细胞市场价值为 12.2 亿美元，预计在预测期内将强劲成长，到 2028 年CAGR为 9.65%。

全球诱导多能干细胞（iPSC）市场已成为再生医学和细胞治疗领域充满活力且前景广阔的领域。 iPSC 是一种特殊细胞，可以从成体细胞产生并重新编程以表现出多能特性，使其成为研究和治疗应用的宝贵资源。全球 iPSC 市场的主要驱动力之一是对个人化医疗和再生疗法的需求不断增长。 iPSC 提供了一个独特的机会来开发针对患者的治疗方法，降低免疫排斥的风险并提高治疗效果。製药公司、学术机构和生技公司正在大力投资 iPSC 研究，以开发针对多种疾病的新疗法，包括心血管疾病、神经退化性疾病和糖尿病。此外，由于 CRISPR-Cas9 等基因组编辑技术的进步，iPSC 市场出现了大幅成长，该技术能够精确操作 iPSC 以进行疾病建模和药物发现。这为标靶治疗的开发和遗传性疾病的研究开闢了新的途径。此外，慢性病盛行率的上升和人口老化增加了对创新医疗解决方案的需求，进一步推动了 iPSC 市场的成长。然而，围绕 iPSC 研究的监管障碍和伦理问题等挑战仍然是重大障碍。确保 iPSC 的安全和道德使用至关重要，世界各地的监管机构正在努力为其生产和应用制定指南和标准。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	12.2亿美元
2028 年市场规模	21.1亿美元
2023-2028 年CAGR	9.65%
成长最快的细分市场	药物开发
最大的市场	北美洲

慢性病盛行率增加

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依衍生细胞类型（肝细胞、纤维母细胞、角质形成细胞、神经元等）
  • 按应用（药物开发、再生医学、毒性测试、组织工程、细胞治疗、疾病模型）
  • 按最终用户（研究机构、其他）
  • 按公司划分 (2022)
  • 按地区
• 市场地图

第 6 章：北美诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按衍生细胞类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按衍生细胞类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按衍生细胞类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按衍生细胞类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲诱导多能干细胞市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按衍生细胞类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非诱导性多能干细胞
  • 沙乌地阿拉伯诱导多能干细胞
  • 阿联酋诱导多能干细胞

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • LizarBio Therapeutics (Pluricell Biotech)
  • Reprocell USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.

策略建议

Global Induced Pluripotent Stem Cells Market has valued at USD 1.22 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.65% through 2028.

The global induced pluripotent stem cells (iPSCs) market has emerged as a dynamic and promising sector within the field of regenerative medicine and cell therapy. iPSCs are specialized cells that can be generated from adult cells and reprogrammed to exhibit pluripotent properties, making them a valuable resource for research and therapeutic applications. One of the primary drivers of the global iPSCs market is the increasing demand for personalized medicine and regenerative therapies. iPSCs offer a unique opportunity to develop patient-specific treatments, reducing the risk of immune rejection and enhancing treatment efficacy. Pharmaceutical companies, academic institutions, and biotechnology firms are investing heavily in iPSC research to develop novel therapies for a wide range of diseases, including cardiovascular disorders, neurodegenerative conditions, and diabetes. Furthermore, the iPSCs market has witnessed substantial growth due to advancements in genome editing technologies such as CRISPR-Cas9, which enable precise manipulation of iPSCs for disease modeling and drug discovery. This has opened new avenues for the development of targeted therapies and the study of genetic disorders. Additionally, the rising prevalence of chronic diseases and an aging population have increased the demand for innovative healthcare solutions, further fueling the iPSCs market's growth. However, challenges such as regulatory hurdles and ethical concerns surrounding iPSC research remain significant roadblocks. Ensuring the safety and ethical use of iPSCs is crucial, and regulatory bodies worldwide are working to establish guidelines and standards for their production and application.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1.22 Billion
Market Size 2028	USD 2.11 Billion
CAGR 2023-2028	9.65%
Fastest Growing Segment	Drug Development
Largest Market	North America

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant driver propelling the growth of the global induced pluripotent stem cells (iPSCs) market. Chronic diseases, such as cardiovascular disorders, neurodegenerative conditions, diabetes, and cancer, have become a pervasive global health challenge, accounting for a substantial portion of healthcare expenditures and posing a substantial burden on patients and healthcare systems alike. Traditional treatment approaches for many of these diseases often provide only symptomatic relief or limited therapeutic options, leaving patients with long-term health issues and a reduced quality of life. iPSCs offer a glimmer of hope by presenting a novel approach to addressing chronic diseases. These reprogrammed cells can be generated from a patient's own tissue, such as skin or blood cells, and then coaxed into differentiating into the specific cell types affected by the disease. This personalized approach not only addresses the genetic and immunological compatibility issues often encountered in transplantation but also holds the potential to provide curative treatments. It allows researchers to study the disease's mechanisms, test potential therapies, and ultimately develop tailored, patient-specific treatments.

The ability to generate iPSC-derived disease models has revolutionized drug discovery and development. Pharmaceutical companies and researchers are increasingly utilizing iPSCs to create accurate cellular models of chronic diseases, enabling them to test potential drug candidates more effectively. This has led to the identification of novel therapeutic targets and the development of drugs that are more likely to succeed in clinical trials, reducing the high attrition rates traditionally associated with drug development. As the prevalence of chronic diseases continues to rise due to factors such as aging populations and lifestyle changes, the demand for innovative treatment options becomes even more pressing. iPSCs, with their potential to provide patient-specific and disease-specific solutions, are well-positioned to meet this demand.

Rising Geriatric Population

The rising geriatric population is a significant factor driving the growth of the global induced pluripotent stem cells (iPSCs) market. Demographic trends across the world indicate a steady increase in the elderly population, a phenomenon attributed to improved healthcare, better living conditions, and advancements in medical science. With this demographic shift, there has also been a proportional increase in age-related diseases and conditions, such as Alzheimer's disease, age-related macular degeneration, and Parkinson's disease. iPSCs offer a promising avenue for addressing the unique healthcare needs of the aging population. These cells can be reprogrammed from a patient's own somatic cells and then differentiated into specific cell types, making them an ideal source for regenerative therapies. As age-related diseases often involve the degeneration or dysfunction of specific cell types, iPSCs can be used to generate healthy replacement cells tailored to the patient's genetic profile. This personalized approach holds immense potential for restoring function and improving the quality of life for elderly individuals suffering from these conditions.

Furthermore, iPSCs are invaluable tools for modeling age-related diseases in the laboratory, allowing researchers to gain insights into disease mechanisms and screen potential drug candidates. These disease models are crucial for developing effective therapies and interventions that can slow down or halt the progression of age-related conditions. The aging population's healthcare needs are placing a growing burden on healthcare systems and resources, driving the demand for innovative and cost-effective treatments. iPSC-based therapies, which have the potential to rejuvenate and repair aging tissues and organs, are becoming increasingly relevant in this context.

Expanding Research Infrastructure

The expansion of research infrastructure is a critical driver behind the growth of the global induced pluripotent stem cells (iPSCs) market. iPSCs hold immense promise for regenerative medicine, disease modeling, and drug discovery, but their realization requires advanced research facilities, equipment, and expertise. As the iPSCs field continues to evolve, research institutions, academic centers, and biotechnology companies are actively investing in building and enhancing research infrastructure to unlock the full potential of iPSCs. Advanced research infrastructure encompasses cutting-edge laboratories equipped with state-of-the-art instruments for cellular reprogramming, differentiation, and genetic editing. These facilities are essential for the generation and manipulation of iPSCs, as well as for conducting experiments related to their applications. As research institutions upgrade their facilities, it becomes easier for scientists to work with iPSCs, accelerating the pace of discoveries and developments.

In addition to laboratory infrastructure, the iPSCs market benefits from the expansion of collaborative networks and research consortia. Many research institutions collaborate across borders, sharing knowledge and resources to advance iPSC research collectively. These collaborations foster interdisciplinary approaches, enabling researchers to address complex challenges more effectively and explore a broader range of applications, from regenerative therapies to disease modeling and drug screening. Furthermore, the growth of research infrastructure has led to the establishment of dedicated iPSC research centers and institutes. These specialized facilities serve as hubs for iPSC-related research, offering specialized training programs and fostering a collaborative environment. They attract top talent in the field and provide critical support for innovation and development in iPSC-based therapies and technologies. The impact of expanding research infrastructure extends beyond academia, influencing the biopharmaceutical industry as well. Pharmaceutical and biotechnology companies are increasingly partnering with research institutions and investing in their own iPSC research centers. This industry-academia collaboration is pivotal for translating iPSC discoveries into clinical applications, ultimately benefiting patients through the development of cutting-edge therapies.

Key Market Challenges

Safety and Efficacy Concerns

Safety and efficacy concerns stand out as a significant hindrance to the growth of the global induced pluripotent stem cells (iPSCs) market. While iPSCs hold immense promise in regenerative medicine and personalized therapies, there are several critical challenges that must be addressed to ensure their clinical application. One of the foremost concerns is the safety of iPSC-based therapies. When iPSCs are used to generate differentiated cell types for transplantation or disease modeling, there is a risk of tumorigenesis. iPSCs can potentially form teratomas, tumors composed of various cell types, when transplanted into patients. These tumorigenic risks pose a substantial obstacle to the clinical translation of iPSC-based treatments, as patient safety must always be paramount. Moreover, immune rejection is another safety concern. Despite being generated from a patient's own cells, iPSC-derived cells may not always be perfectly matched to the patient's immune system. Ensuring compatibility and preventing immune responses is a critical challenge, particularly in allogeneic iPSC-based therapies where cells are derived from donors other than the patient.

In addition to safety concerns, there are efficacy challenges to address. Demonstrating the efficacy of iPSC-based therapies through rigorous preclinical and clinical trials is essential. These therapies must not only be safe but also provide meaningful therapeutic benefits. The complexities of evaluating their long-term efficacy, especially in chronic and degenerative diseases, add to the challenge. Furthermore, standardization of iPSC production and differentiation protocols is essential to ensure consistent and reliable outcomes. Variability in iPSC quality, differentiation efficiency, and the functional characteristics of iPSC-derived cells can hinder the reproducibility of results and the reliability of iPSC-based treatments.

Regulatory Hurdles

Regulatory hurdles represent a significant impediment to the growth of the global induced pluripotent stem cells (iPSCs) market. iPSCs hold immense potential for regenerative medicine and therapeutic applications, but navigating the complex and evolving regulatory landscape poses substantial challenges. One of the primary issues stems from the need to establish comprehensive and consistent regulatory guidelines for iPSCs. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are tasked with ensuring the safety and efficacy of new therapies. However, iPSCs' unique characteristics, including their potential to differentiate into various cell types and the personalized nature of their applications, require tailored regulatory frameworks. The lack of clear and harmonized regulations can create ambiguity and hinder research, development, and clinical translation.

Additionally, iPSC-based therapies often involve genetic modifications, introducing another layer of regulatory complexity. Editing the genetic material of iPSCs raises concerns about safety, off-target effects, and ethical considerations. Regulatory agencies are challenged with developing guidelines that strike a balance between promoting innovation and ensuring patient safety. Furthermore, the time and resources required to navigate the regulatory approval process can be daunting for researchers and companies in the iPSCs market. Clinical trials for iPSC-based therapies often demand extensive data collection, long-term follow-up, and robust safety assessments.

Key Market Trends

Personalized Medicine and Patient-Specific Therapies

One of the most significant trends driving the iPSCs market is the increasing emphasis on personalized medicine. Healthcare providers and researchers are recognizing that one-size-fits-all treatments may not be the most effective approach for many diseases. iPSCs allow for the creation of patient-specific therapies by reprogramming a patient's own cells, reducing the risk of immune rejection and increasing treatment efficacy. This trend aligns with the growing demand for tailored healthcare solutions, particularly in the treatment of chronic and complex diseases. iPSCs provide a powerful tool for developing patient-specific therapies. By reprogramming a patient's own cells into iPSCs, researchers can generate a source of cells that closely match the patient's genetic profile. This personalized approach reduces the risk of immune rejection, enhances treatment efficacy, and minimizes adverse reactions. For patients with genetic disorders, iPSCs offer a beacon of hope. Researchers can correct disease-causing mutations in iPSCs, effectively "fixing" the genetic basis of the disorder. These corrected iPSCs can then be differentiated into the required cell types, providing a potential cure for conditions that were previously considered untreatable. iPSCs allow for the creation of disease models that replicate the unique characteristics of a patient's ailment. These models enable researchers to study disease mechanisms, test potential therapies, and develop personalized treatment strategies. iPSC-derived disease models enhance our understanding of complex diseases, driving innovation in treatment approaches. Patient-specific iPSC-based therapies hold the promise of reducing adverse effects commonly associated with traditional treatments. By closely matching the patient's genetic and immunological profile, iPSC-derived cells are more likely to be tolerated by the body, minimizing side effects and improving overall treatment outcomes.

Advancements in Genome Editing Technologies

Advancements in genome editing technologies, notably CRISPR-Cas9, have revolutionized iPSC research. These tools enable precise genetic modifications in iPSCs, making it possible to correct disease-causing mutations and develop more accurate disease models. Researchers can now study the genetic basis of various conditions and develop targeted therapies with greater efficiency. This trend has accelerated drug discovery efforts and has further increased the appeal of iPSCs in the biopharmaceutical industry. CRISPR-Cas9 allows scientists to make precise modifications to the genetic material of iPSCs. This capability is invaluable for creating disease models and developing potential cures. Researchers can correct genetic mutations associated with various diseases, providing a deeper understanding of their underlying mechanisms and accelerating the discovery of novel therapies. iPSCs, when combined with genome editing, enable the development of sophisticated disease models. Researchers can introduce disease-specific mutations or correct faulty genes to mimic specific diseases in a laboratory setting. These models provide a realistic platform for studying disease progression, testing potential treatments, and gaining insights into disease mechanisms. Genome editing allows for the creation of iPSCs that are custom-tailored to an individual patient's genetic profile. This is a significant step toward personalized medicine. By reprogramming a patient's own cells and precisely modifying them as needed, researchers can generate iPSC-derived cells for transplantation or disease modeling that are inherently compatible with the patient's immune system. The combination of iPSCs and genome editing has revolutionized drug discovery efforts. iPSC-derived cells carrying disease-specific mutations provide a more physiologically relevant platform for evaluating the safety and efficacy of new drug candidates. This reduces the risk of drug failures in later stages of development, saving time and resources for pharmaceutical companies.

Segmental Insights

Application Insights

Based on the application, the drug development segment emerged as the dominant player in the global market for Global Induced Pluripotent Stem Cells in 2022. This is on account of several growing key factors including Efficient Drug Discovery, Disease Modeling and increase in personalized medicine. iPSCs have emerged as a critical tool for accelerating drug discovery efforts. They enable pharmaceutical companies to create human-specific disease models, which closely mimic the physiological conditions in the human body. This accuracy enhances the efficiency of drug screening and helps identify potential candidates more quickly.

Derived Cell Type Insights

Based on the Derived Cell Type, the hepatocytes segment emerged as the dominant player in the global market for Global Induced Pluripotent Stem Cells in 2022. This is on account of Hepatocytes being a critical cell type in the iPSCs market, primarily due to their significant role in liver disease modeling, drug metabolism studies, and drug toxicity testing. They are essential for understanding how drugs are processed in the liver and for identifying potential liver-related side effects of pharmaceutical compounds. Hepatocytes are also used to study liver diseases such as hepatitis and cirrhosis, making them a valuable asset in drug development and disease research.

Regional Insights

North America emerged as the dominant player in the global Induced Pluripotent Stem Cells market in 2022, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, Strong Research and Development Ecosystem and high regulatory acceptance.

Key Market Players

Axol Bioscience Ltd.

Cynata Therapeutics Limited

Evotec SE

Fate Therapeutics, Inc.

FUJIFILM Cellular Dynamics, Inc.

Ncardia

LizarBio Therapeutics (Pluricell Biotech)

Reprocell USA, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Takara Bio, Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Induced Pluripotent Stem Cells Market, By Derived Cell Type:

• Hepatocytes Fibroblasts
• Keratinocytes
• Neurons
• Others

Global Induced Pluripotent Stem Cells Market, By Application:

• Drug Development
• Regenerative Medicine
• Toxicity Testing
• Tissue Engineering
• Cell Therapy
• Disease Modeling

Global Induced Pluripotent Stem Cells Market, By End User:

• Research Institutions
• Other

Global Induced Pluripotent Stem Cells Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.

Available Customizations:

• Global Induced Pluripotent Stem Cells market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others)
  • 5.2.2. By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling)
  • 5.2.3. By End user (Research Institutions, Other)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Derived Cell Type
  • 6.2.2. By Application
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Induced Pluripotent Stem Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Derived Cell Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End user
  • 6.3.2. Mexico Induced Pluripotent Stem Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Derived Cell Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End user
  • 6.3.3. Canada Induced Pluripotent Stem Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Derived Cell Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End user

7. Europe Induced Pluripotent Stem Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Derived Cell Type
  • 7.2.2. By Application
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Induced Pluripotent Stem Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Derived Cell Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End user
  • 7.3.2. Germany Induced Pluripotent Stem Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Derived Cell Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Derived Cell Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Induced Pluripotent Stem Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Derived Cell Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Induced Pluripotent Stem Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Derived Cell Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End user

8. Asia-Pacific Induced Pluripotent Stem Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Derived Cell Type
  • 8.2.2. By Application
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Induced Pluripotent Stem Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Derived Cell Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End user
  • 8.3.2. India Induced Pluripotent Stem Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Derived Cell Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End user
  • 8.3.3. South Korea Induced Pluripotent Stem Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Derived Cell Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End user
  • 8.3.4. Japan Induced Pluripotent Stem Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Derived Cell Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Induced Pluripotent Stem Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Derived Cell Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End user

9. South America Induced Pluripotent Stem Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Derived Cell Type
  • 9.2.2. By Application
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Induced Pluripotent Stem Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Derived Cell Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End user
  • 9.3.2. Argentina Induced Pluripotent Stem Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Derived Cell Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End user
  • 9.3.3. Colombia Induced Pluripotent Stem Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Derived Cell Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End user

10. Middle East and Africa Induced Pluripotent Stem Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Derived Cell Type
  • 10.2.2. By Application
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Induced Pluripotent Stem Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Derived Cell Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End user
  • 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Derived Cell Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End user
  • 10.3.3. UAE Induced Pluripotent Stem Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Derived Cell Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Axol Bioscience Ltd.
  • 15.6.2. Cynata Therapeutics Limited
  • 15.6.3. Evotec SE
  • 15.6.4. Fate Therapeutics, Inc.
  • 15.6.5. FUJIFILM Cellular Dynamics, Inc.
  • 15.6.6. Ncardia
  • 15.6.7. LizarBio Therapeutics (Pluricell Biotech)
  • 15.6.8. Reprocell USA, Inc.
  • 15.6.9. Sumitomo Dainippon Pharma Co., Ltd.
  • 15.6.10. Takara Bio, Inc.

Strategic Recommendations